Squamous Cell Carcinoma of the Head and Neck – Epidemiology – Middle East & Africa

Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of squamous cell carcinoma of the head and neck for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and over a period of 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.

Clarivate Epidemiology’s squamous cell carcinoma of the head and neck forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with squamous cell carcinoma of the head and neck per year?
• Of all people diagnosed with squamous cell carcinoma of the head and neck, how many in each country across the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of squamous cell carcinoma of the head and neck over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts over 100 squamous cell carcinoma of the head and neck patient populations, as follows:

• Locoregionally advanced non-nasopharyngeal drug-treated.
• First–line metatstatic DTP – nasopharynx.
• Other SCCHN– stage IVB.
• Diagnosed incident cases – nasopharynx – stage IVA.
• Diagnosed prevalent cases of HPV–negative oropharynx cancer.
• Diagnosed incident cases – nasopharynx EBV–negative.
• Second–line non-nasopharyngeal drug-treated.
• Diagnosed incident cases – nasopharynx cancer.
• … and many more (details available on request).

Note: Coverage may vary by country.